Illinois · Nonprofit
FOUNDATION FOR SARCOIDOSIS RESEARCH
FOUNDATION FOR SARCOIDOSIS RESEARCH (Illinois) receives grants from 62 organizations whose IRS filings report $13,966,615 to it, the largest being DRUCKENMILLER FOUNDATION ($10,350,000). 37 of them have funded it in more than one year.
- Revenue FY2025
- $4.7M
- Funders on record
- 62
- Grants received
- $14M
- Net assets
- $18M
What Foundation for Sarcoidosis Research does
Mission
The Foundation for Sarcoidosis Research (fsr) is the leading international organization dedicated to finding a cure for sarcoidosis and improving care for sarcoidosis patients through research, education, and support. Since its establishment in 2000, fsr has fostered over $7.5 million in sarcoidosis specific research efforts.
As stated on its FY2025 Form 990.
Programs
On its FY2025 return the organization reported starting a significant new program.
1) biomarker summit- building on a comprehensive, community-engaged process to develop fsr's sarcoidosis research agenda (the report which was finalized in 2025) to guide its funding priorities and long-term scientific strategy, fsr hosted a meeting of world-renowned sarcoidosis experts to develop a initiate the discussion of how biomarkers are defined, their primary purpose, and how they can advance clinical outcomes. The goal of this program was to create a roadmap for the development of consensus-defined biomarkers which will be used to improve diagnosis, screening, and research. 2) in-person fsr global sarcoidosis clinic alliance meeting - this convening of nearly 30 sarcoidosis centers offered the opportunity for clinicians to come together to discuss clinical best practices and strategies to improve every day clinical cares and support of sarcoidosis patients. 3) fsr sarc registry 10 year report - this global, patient-reported outcomes program incorporates dates from 2015-2025. For a decade, the fsr registry has gathered crucial information from individuals living with sarcoidosis around the world. This online patient registry is helping researchers uncover patterns in the disease and identify ways to improve care and quality of life. 4) fsr sarcoidosis voice of the patient report - the Foundation for Sarcoidosis Research hosted the externally-led patient focused drug development (el-pfdd) meeting with the us food and drug administrationan interactive, virtual event…
Its own explanation, from Schedule O of that return (Part III, line 2).
Fsr research funding - the Foundation for Sarcoidosis Research provided $875,600 in sarcoidosis research funding in 2025. Fsr provided three fellowships in the amount of $150,000 each, two cardiac grants in the amount of $100,000 each, two pilot grants in the amounts of $100,000 and $99,600, and one fsr/american heart association partner grant in the amount of $26,000. Fsr also hosts a patient registry with nearly 7,500 participants from 68 countries and provides ongoing support to academia and industry in ensuring all clinical trials and research are patient centered.
$1,553,084 spentof which $844,600 as grants$85,903 earned by the program54% of program spendingFsr global sarcoidosis clinic alliance (fsr-gsca) clinical support - comprised of 46 member institutions, the fsr-gsca is a powerful network of institutions that support patients, caregivers, and clinicians, through educational and support programming. The fsr-gsca reaches over 4000 clinicians with clinical education programming from over 40 countries. Through this program, fsr coordinates continuing education educational programs for clinicians including the fsr clinical education and engagement series, the fsr journal club, and the fsr case conference program, which provide insights that lead to practice changing behavior by attendees and participants. Fsr is now supporting regional clinical education meetings through program and marketing support to reach beyond experts to the pool of local physicians and advanced practitioners.
$1,096,474 spentof which $31,000 as grants$11,364 earned by the program38% of program spendingFsr patient support and education - fsr provides extensive support to patient and caregivers impacted by sarcoidosis through information & referral services, assistance to financial resources, 1:1 peer to peer patient support program (patient navigators), national virtual support group, and local support groups affiliated with the fsr global sarcoidosis clinic alliance. Fsr hosts webinars, town halls, podcasts, virtual summits, and in-person educational events to provide patients and family members with education from world-renowned sarcoidosis experts. Fsr works with the nih, fda, and dod to ensure the sarcoidosis is considered in all aspects for federal research and drug development. Fsr is committed to ensuring clinical trials represent all in our community and has been leading efforts to reduce barriers to clinical trial access, including coverage under fmla and paid time off.
$215,975 spent8% of program spending
The 3 programs described on its FY2025 Form 990, listed largest first by expense. Program spending in total: $2,865,533.
The organization over time
Each line starts at 100 in 2017, so what you read is the shape rather than the size: 150 means half as much again as 2017, 50 means half. The number beside each label in the key is where it ended. The shaded band is where the middle 50% of its peers' revenue would sit, given their growth.
Balance sheet
Total assets and total liabilities at each year end, in dollars. The largest one-year move in total assets was 2023 to 2024, from $5.7M to $17M (+199%).
How it's funded, over time
Each bar is one year's revenue split into where it came from, and every bar is the same height — these are shares, not amounts, so a year that raised twice as much looks the same size. Hover a bar for the split.
Government-grant reliance: 2020 7% · 2023 8%. Grants only. Government contracts and fees sit inside program revenue.
85% of FOUNDATION FOR SARCOIDOSIS RESEARCH’s revenue is contributions — more donation-reliant than the typical peer (82% for the typical peer).
Surplus & reserves
Operating surplus or deficit each year, and months of liquidity in hand. 2 of the last 9 reported years ran a deficit.
reserve
Leadership and staff
The officers, directors, trustees and key employees listed on each return. Joined and no longer listed compare each filing with the year before, matching people by surname and first initial; a year after a gap, or a roster under three people, has no comparison.
Chief executive
Mary Mcgowan
President & CEO
As listed on its FY2025 Form 990.
The chief executive listed changed between the FY2019 and FY2020 filings.
Who funds it, year by year
2017 → 2023: the base broadened from 10 funders to 20 funders, grant income rose $159k → $688k.
16 of 62 of your funders are donor-advised or pass-through sponsors (tagged DAF) — 19% of grant dollars received. That money is really individual donors directing a sponsor; the institutions to cultivate are the non-DAF funders.
From the IRS filings of FOUNDATION FOR SARCOIDOSIS RESEARCH’s funders (the co-funder graph). Top 30 of 62 funders by total. Association, not causation. Trends are read to FY2023, the last fiscal year that has finished arriving. FY2024–FY2026 are still being filed and are shown unshaded; they do not move any figure on this page.
How concentrated its funding is
FOUNDATION FOR SARCOIDOSIS RESEARCH leans on a few funders — its largest provides 74% of grant income and the top three 85%; half comes from just 1 funder.
the vertical line marks half of all grant income — 1 funder to its left
Largest funder’s share by year: 2017 43% · 2018 41% · 2019 54% · 2020 34% · 2021 69% · 2022 16% · 2023 51% — growing more concentrated.
“Effective funders” = inverse Herfindahl index (1 / Σ shareᵢ²) — the number of equal-sized funders that would give the same concentration. Trends are read to FY2023, the last fiscal year that has finished arriving. FY2024–FY2026 are still being filed and are shown unshaded; they do not move any figure on this page.
How long its funders stay
36% of FOUNDATION FOR SARCOIDOSIS RESEARCH's funders are still giving 3 years after their first grant; 60% give in more than one year at all.
Share of funders still giving k years after their first recorded grant, pooled across every acquisition cohort. A funder counts as retained in a year only if it made a grant that year. Measured to FY2023, the last fiscal year that has finished arriving — a funder cannot be counted as lapsed in a year most filers have not reached.
Where its funders are
FOUNDATION FOR SARCOIDOSIS RESEARCH draws 98% of its grant income from funders outside Illinois, across 20 states in all.
In-state vs out-of-state, by year
Funder states come from each funder’s own filing. $2.7M arriving through sponsors registered in 11 states is excluded from the map and the split above: a sponsor holds money on a donor’s behalf, so its registered address would place those dollars somewhere no donor need ever have been. Trends are read to FY2023, the last fiscal year that has finished arriving. FY2024–FY2026 are still being filed and are shown unshaded; they do not move any figure on this page.
Against its field
FOUNDATION FOR SARCOIDOSIS RESEARCH holds deeper cash reserves than three-quarters of the 1,645 philanthropy nonprofits its size.
this organization peer median middle 50% of peers· 1,645 philanthropy nonprofits $1M–$10M, FY2025
Organizations like FOUNDATION FOR SARCOIDOSIS RESEARCH
Organizations whose mission and program text most resemble this one, by semantic similarity over every organization in the US filings — the closest peers, and often the clearest route to shared or prospective funders.
In Illinois
Nationally
Read directly from this organization’s own Form 990, as neutral context.
Where the money goes
75% of spending goes to programs.
Governance
Public support
38%
Share of support from the public (Schedule A) — the basis for its public-charity status.
Footprint & structure
Files a return copy in 1 state
Screen this organization
A dated, signed PDF of the compliance screen for FOUNDATION FOR SARCOIDOSIS RESEARCH: IRS status (Business Master File, Publication 78, auto-revocation), the OFAC sanctions lists, the Internal Revenue Bulletin, and California registration, with the Rev. Proc. 2018-32 §8.01 reliance elements stated element by element. Generated from the current files at the moment you download it.
Screens are triage, not determinations; a source that cannot be read reports not screened, never clear. Screen this nonprofit · How the screen works · on the API as GET /api/screening/{ein}?format=pdf
Questions and answers
- Who funds FOUNDATION FOR SARCOIDOSIS RESEARCH?
- FOUNDATION FOR SARCOIDOSIS RESEARCH (Illinois) receives grants from 62 organizations whose IRS filings report $13,966,615 to it, the largest being DRUCKENMILLER FOUNDATION ($10,350,000). 37 of them have funded it in more than one year.
- How many funders does FOUNDATION FOR SARCOIDOSIS RESEARCH have?
- IRS filings report 62 organizations giving $13,966,615 in grants to FOUNDATION FOR SARCOIDOSIS RESEARCH, 37 of which have funded it in more than one year.
- Who is the largest funder of FOUNDATION FOR SARCOIDOSIS RESEARCH?
- DRUCKENMILLER FOUNDATION is the largest funder on record, with $10,350,000 in grants. The full list of funders is on this page.
- How can an organization like FOUNDATION FOR SARCOIDOSIS RESEARCH find more funders?
- Start with the funders already giving here, then look at the foundations that back similar organizations in Illinois. The funding by cause and by state pages list the largest funders for a given area and how to approach them.
These figures are read directly from IRS Form 990 / 990-PF e-file XML: this organization’s own return for FY2025 (financials across 2017–2025), and the filings of 62 funders that report grants to it. “On record” means captured in the filings we have parsed — a funder that does not e-file, or whose grant detail is not itemized, will not appear. Filings run roughly 12–24 months behind. Trends on this page end at FY2023, the last fiscal year that has finished arriving; later years are shown and marked, and move no figure. Data on this page was exported October 22, 2026. What this page cannot tell you · view filing